The adenomatous polyposis coli (APC) protein is a negative regulator of the mitogenic transcription factor b-catenin by stimulating its proteasomal degradation. This involves several APC domains, including the binding sites for axin/conductin, the recently described b-Catenin Inhibitory Domain (CID) and the third 20 amino acid repeat (20R3) that is a b-catenin-binding site. The four 15 amino acid repeats (15R) and the 20R1 are also b-cateninbinding sites, but their role in b-catenin degradation has remained unclear. We show here that binding of b-catenin to the 15R of APC is necessary and sufficient to target b-catenin for degradation whereas binding to the 20R1 is neither necessary nor sufficient. The first 15R displays the highest affinity for b-catenin in the 15R-20R1 module. Biallelic mutations of the APC gene lead to colon cancer in familial adenomatous polyposis coli (FAP) and result in the synthesis of truncated products lacking domains involved in b-catenin degradation but still having a minimal length. The analysis of the distribution of truncating mutations along the APC sequence in colorectal tumours from FAP patients revealed that the first 15R is one target of the positive selection of mutations that lead to tumour development.
Introduction
Familial adenomatous polyposis coli is an autosomal dominant genetic disorder characterized by the germline transmission of a mutation in the adenomatous polyposis coli gene (Groden et al., 1991 Olschwang et al., 1993) . Somatic inactivation of the remaining allele leads to the development of polyps in the gastrointestinal tract that ultimately evolve as aggressive and fatal tumours in affected people. Besides gastric, duodenal and colorectal cancer, familial adenomatous polyposis coli (FAP) patients may also develop desmoid tumours (Kotiligam et al., 2008) .
Many functions have been attributed to adenomatous polyposis coli (APC) (Nathke, 2006; Akiyama and Kawasaki 2006; Aoki and Taketo 2007; Schneikert and Behrens, 2007a; McCartney and Nathke, 2008) , but it is best understood as a component of the canonical wnt signalling pathway, controlling the fate of the transcription factor b-catenin (Clarke, 2006; Clevers, 2006; Taketo, 2006; Polakis, 2007; Fodde and Brabletz 2007) . In the presence of a proliferative signal provided by an extracellular ligand from the wnt family, cytosolic b-catenin accumulates, translocates into the nucleus and stimulates the transcription of target genes (Behrens et al., 1996) . Thereby, b-catenin translates the wnt signal into changes in the transcriptional state that ultimately manifest by cell proliferation. In the absence of a wnt signal, b-catenin is destroyed in the proteasome where it is conveyed only after a critical phosphorylation step catalysed in the so-called degradation complex (Kimelman and Xu, 2006) . In this complex, axin/ conductin recruits the kinases glycogen synthase kinase 3b and casein kinase 1 that sequentially phosphorylate b-catenin (Liu et al., 2002) . This process is drastically enhanced by the presence of APC (Munemitsu et al., 1995) that displays several domains involved in bcatenin degradation (Figure 1 ). The SAMP repeats constitute binding sites for axin/conductin (Behrens et al., 1998) . The seven 20 amino acid repeats (20R) are b-catenin-binding sites (Rubinfeld et al., 1993) . Among the latter, a role in b-catenin degradation has been demonstrated in detail for the third 20R (20R3) only (Rubinfeld et al., 1997; Kohler et al., 2008) . In contrast, the 20R2 cannot bind to b-catenin (Liu et al., 2006; Kohler et al., 2008) . Phosphorylation of the 20R1 and the 20R3 increases their affinity for b-catenin (Tickenbrock et al., 2003; Ha et al., 2004; Xing et al., 2004; Liu et al., 2006; Ferrarese et al., 2007) . The b-Catenin Inhibitory Domain (CID) domain is located between the 20R2 and the 20R3 and is essential in truncated APC to target b-catenin for degradation (Kohler et al., 2009) . The four 15 amino acid repeats (15R-A to D) are also bcatenin-binding sites (Su et al., 1993; Eklof Spink et al., 2001; Liu et al., 2006) , but it is not known whether they have a role in b-catenin degradation.
APC mutations as found in the germline of FAP patients lead to premature termination of translation and therefore to the synthesis of truncated products (Miyoshi et al., 1992; Powell et al., 1992; Miyaki et al., 1994 Miyaki et al., , 2008 Segditsas and Tomlinson, 2006) . Mutations of both APC alleles in FAP tumours are interdependent, that is, the site of the germline mutation determines the nature and the location of the somatic mutation (Lamlum et al., 1999; Rowan et al., 2000; Albuquerque et al., 2002; Crabtree et al., 2003) . This results in a complex distribution of APC mutations along the sequence, which is partially explained by the necessity of removing or inactivating important domains involved in the degradation of b-catenin (that is, the SAMP repeats, the 20R3 and the CID domain). As a consequence, b-catenin is constitutively stabilized. The SAMP repeats and the 20R3 are almost systematically excluded from truncated APC (Kohler et al., 2008) . The necessity of removing both domains is illustrated by the availability of mice heterozygous for APC isoforms truncated either shortly after the first SAMP repeat (APC þ /1638T mice) (Smits et al., 1999) or between the 20R3 and the first SAMP repeat (APC þ /1572T mice) (Gaspar et al., 2009 ). These animals do not develop tumours in the gastrointestinal tract. In some cases however, the CID domain that allows truncated APC to target b-catenin for degradation even in the absence of the 20R3 and the SAMP repeats in the appropriate cell line, can be retained in a colorectal tumour if additional molecular events lead to its inactivation (Kohler et al., 2009) . Thus, APC truncated shortly after the CID can be used experimentally to target efficiently b-catenin for degradation if it is expressed in a permissive cell line. Despite the negative selection, colon cancer cells always retain a truncated APC of a minimal length. In 95% of the cases the fragment extends up to at least the end of the 20R1 (Kohler et al., 2008) . At the molecular level, the reasons of this positive selection are not known, but its strength indicates that the retained fragment probably fulfils an essential function. Actually, RNA interference experiments have shown that APC truncated shortly after the 20R1 and lacking the CID domain, is required for optimal cell proliferation (Schneikert and Behrens, 2006) and can still exert a control on the transcriptional activity of b-catenin (Schneikert et al., 2007b) . This is in line with the recent analysis of APC þ /1322T mice (Pollard et al., 2009 ) carrying an APC truncation falling shortly after the 20R1. These mice display a more severe polyposis but polyps with lower amounts of nuclear b-catenin than in mice, in which truncated APC does not contain any b-catenin-binding site. The positive selection rule is not absolute and tolerates 5% of exceptions in which APC is truncated before the 20R1. In these cases, it is not known which APC domain is the target of the positive selection.
In this communication, we provide evidence that the 15R are important b-catenin-binding sites involved in APC-mediated degradation of b-catenin and the first 15R is one parameter of the positive selection of APCtruncating mutations in tumours from FAP patients.
Results
The contribution of the b-catenin-binding sites of APC to b-catenin degradation was first investigated in an APC construct tagged at its N terminus with YFP and extending up to amino acid 1641, shortly after the first axin/conductin-binding site ( Figure 1 ). Such a construct was previously shown to inhibit b-catenin-dependent transcription and target b-catenin for degradation (Kohler et al., 2009) . Mutations that either inactivate b-catenin binding to the 20R1 and the four 15R, or drastically reduce the association of b-catenin to the 20R3 as described previously (Kohler et al., 2008) were introduced in the construct, either individually or in all possible combinations. The resulting plasmids were transiently transfected in SW480 colon cancer cells that contain relatively high levels of cytosolic b-catenin, and expression was monitored by western blotting using an anti-GFP antibody. The fluorescence of YFP allowed also revealing the intracellular localization of the YFP-APC fusions. The consequences on b-cateninmediated transcription were measured by co-transfecting a b-catenin-dependent luciferase reporter construct (see Materials and methods section). In parallel, the fraction of transfected cells negative for b-catenin was determined by immunofluorescence staining using an anti-b-catenin antibody. The latter two assays reflect the ability of an APC construct to target b-catenin for degradation (Kohler et al., 2009) . All transfected constructs were expressed at a similar level and displayed an identical diffuse and cytoplasmic intracellular localization (Figure 1 ). YAPC1641 efficiently downregulated the transcriptional activity of b-catenin and none of the transfected cells stained positive for b-catenin. Thus, yAPC1641 targets b-catenin efficiently for degradation. Mutating any of the b-catenin-binding sites, either alone or in a combined manner led only to a modest reduction of the activity of yAPC1641. Even a construct in which all repeats were mutated to abolish any possibility of b-catenin binding (as in yAPC1641-15Rm-20R1m-20R3 mm) (Kohler et al., 2008) was still displaying a considerable b-catenin downregulating activity ( Figure 1 ). In contrast, this activity was lost when the SAMP repeat was deleted from the latter construct (as in yAPC1519-15Rm-20R1m-20R3 mm). We concluded that the SAMP repeat, which provides an interaction surface for axin/conductin confers a high bcatenin-degrading efficiency to APC even in the absence of any functional b-catenin-binding site.
In colon cancer, the SAMP repeats and the 20R3 are lost. However, our previous results have shown that truncated APC lacking these domains but retaining the CID can still efficiently target b-catenin for degradation upon expression in a permissive cell line (Kohler et al., 2009) . Therefore, to reveal a possible involvement of the 15R in b-catenin degradation, we used a construct lacking both SAMP repeat and 20R3 but extending up to amino acid position 1466, that is, after the CID (Figure 2 ). When transiently expressed in SW480 cells, yAPC1466 targeted b-catenin for degradation and inhibited its transcriptional activity, as previously described (Kohler et al., 2009) . Introducing mutations that abolished b-catenin binding to the four 15R (as in yAPC1466-15Rm) led to a very strong reduction of the b-catenin downregulating activity of yAPC1466 (Figure 2 ). We confirmed that the 15R are important determinants of b-catenin degradation by mutating them in additional constructs extending up to amino acid positions 1558, 1519 and 1502 (supplementary Figure 1) . Thus, the 15R of truncated APC are necessary for targeting b-catenin to degradation. Mutation of the (Figure 2) . Thus, we concluded that the 15R are sufficient to target b-catenin for degradation, whereas the 20R1 is not necessary to perform the function. YAPC1466-15Rm containing only the 20R1 as a functional binding site did not affect the transcriptional activity of b-catenin or its level (Figure 2 ). High-affinity b-catenin binding to the 20R has been shown previously to require their phosphorylation (Tickenbrock et al., 2003; Ha et al., 2004; Xing et al., 2004; Liu et al., 2006; Ferrarese et al., 2007) . We verified that this phosphorylation event indeed occurs in SW480 cells (supplementary Figure 2) and concluded that the 20R1 is not sufficient for targeting b-catenin for degradation. Finally, the simultaneous mutations of both 15R and 20R1 (as in yAPC1466-15Rm-20R1m) fully inactivated the molecule (Figure 2 ), indicating that b-catenin binding to yAPC1466 is necessary to target b-catenin for degradation.
In the subsequent experiments, we investigated the individual contributions of each 15R to the b-catenin downregulating activity of yAPC1466 (Figure 3) . In a first step, we designed the yAPC1466-15RBmCmDm-20R1m and yAPC1466-15RAmCmDm-20R1 m constructs in which all b-catenin-binding sites were mutated except the 15R-A or the 15R-B, respectively (Figure 3a) . In addition, we also created the yAPC1466-15RCmDm-20R1m construct, in which both 15R-A and 15R-B were preserved. YAPC1466-15RBmCmDm-20R1m and yAPC1466-15RAmCmDm-20R1m were both reducing the level of b-catenin and inhibiting b-catenin-mediated transcription, although they could not reach the activity of yAPC1466-20R1m (Figure 3a) . Thus, the 15R-A and 15R-B are involved in b-catenin degradation and can work independently of the other repeats. Combining both 15R-A and 15R-B in the same construct (yAPC1466-15RCmDm-20R1m) resulted in a better efficiency. There was some quantitative discrepancy between the reporter assay and the b-catenin degradation assay, but the data matched in a qualitative way. When lower amounts of expression vectors were transfected, the b-catenin downregulating activity of the construct containing the 15R-B decreased but not that of the construct containing the 15R-A, indicating different activities of the repeats (Figure 3b ). Under these conditions, the construct combining both 15R-A and 15R-B was more efficient than the construct containing the 15R-A alone, suggesting a cooperation between the repeats (Figure 3b) .
To understand the difference of b-catenin downregulating activity associated with the 15R-A and 15R-B of APC, we performed immunoprecipitation experiments using cell extracts from transiently transfected HEK293T cells, that we mixed with extracts from SW480 cells to provide a source of b-catenin (Figure 3c ). We found that the constructs displaying a functional 15R-A were binding efficiently to b-catenin, similarly to yAPC1466-20R1m. In contrast, the construct retaining Figure 3 The 15R-A is more potent than the 15R-B to bind b-catenin, target it for degradation and inhibit its transcriptional activity. (a), Transcriptional assay using 1 mg of the indicated constructs and immunofluorescence assay conducted as described in the Figure 1 legend. (b), Transcriptional assay using 10 ng of the indicated constructs. (c), Immunoprecipitation experiment using extracts from HEK293T cells transiently transfected with the constructs indicated in (b). Cell extracts were prepared 40 h post-transfection and mixed with an extract provided by SW480 cells (input). Immunoprecipitation was performed using an anti-GFP antibody (IP-GFP) followed by western blottings using either an anti-GFP or an anti-b-catenin antibody, as indicated. *Po0.02, using the Student's t-test.
the 15R-B only (yAPC1466-15RAmCmDm-20R1m) failed to bind b-catenin. Thus, the 15R-A has a higher affinity for b-catenin than the 15R-B.
To compare the binding affinity of the 15R-A with that of the other repeats, we repeated the immunoprecipitation experiment using constructs in which the 15R were sequentially mutated (Figure 4a) . Mutation of the 15R-A alone (as in yAPC1466-15RAm) led to a pronounced reduction of the b-catenin-binding activity. Further mutating the remaining 15R (as in yAPC1466-15RAmBm, yAPC1466-15RAmBmCm and yAPC1466-15Rm) did not exacerbate substantially the consequence of mutating the 15R-A alone. We found that mutating the 20R1 led to a relatively modest reduction of the b-catenin-binding activity (compare yAPC1466 and yAPC1466-20R1m in Figure 4a ), although we could confirm phosphorylation of the 20R1 in HEK293T cells too (data not shown). Finally, the introduction of inactivating mutations in all b-catenin-binding sites abolished effectively the interaction of truncated APC with b-catenin (as in yAPC1466-15Rm-20R1m). The strong decrease in b-catenin binding achieved upon mutation of the 15R-A alone indicated that this repeat displays the highest affinity for b-catenin among all b-catenin-binding sites in yAPC1466. This conclusion was confirmed in additional immunoprecipitation experiments using constructs in which the 20R1 and the 15R were sequentially deleted (supplementary Figure 3) .
When the constructs in which the 15R were sequentially mutated were transiently transfected in SW480 cells (Figure 4b ), we observed that mutation of the 15R-A alone affected only slightly the b-catenin downregulating activity of yAPC1466 in both transcriptional and immunofluorescence assays. This indicates a compensatory effect from the remaining 15R despite the strong reduction of b-catenin binding. The discrepancy between the immunoprecipitation (Figure 4a ) and the transcriptional and immunofluorescence assays (Figure 4b ) likely comes from the fact that both APC and b-catenin concentrations were higher in the latter assays where they may have reached values near the Kd of the 15R-B (Liu et al., 2006) . In contrast, a construct containing both mutated 15R-A and 15R-B was strongly affected, confirming the involvement of the 15R-B in b-catenin downregulation. In addition, mutating the 15R-C virtually abolished the inhibitory activity of APC toward b-catenin and therefore revealed the contribution of the 15R-C. As already shown above (Figure 2 ), yAPC1466 lacking all functional b-cateninbinding sites was fully inactive, whereas mutation of the 20R1 had only a marginal effect (Figure 4b ). All constructs were expressed at a similar level and displayed indistinguishable intracellular localizations (Figure 4b ). We concluded that the 15R-B and the 15R-C confer a b-catenin downregulating activity to yAPC1466.
In tumours from FAP patients, most truncated APC molecules retain the 20R1 ( Figure 5 ). Out of 227 tumours in which APC does not display the CID domain, 211 contain at least one APC mutation occurring after position 1283, that is, after the 20R1 (Lamlum et al., 1999; Albuquerque et al., 2002; Crabtree et al., 2003; Miyaki et al., 2008) . When a germline mutation occurs before the 20R1 (before position 1271), most second hits are located after it, indicating a selective pressure towards its retention. Inversely, when the truncated APC product resulting from the germline mutation already contains the 20R1, the second allele is lost in most cases. LOH proceeds essentially by homologous recombination (Gupta et al., 1997; Haigis and Dove 2003) resulting in the duplication of the allele containing the truncating mutation. Importantly, as homologous recombination is spontaneously much more frequent than any other mutational event (Hong et al., 2007) , LOH indicates that there is no other selective pressure beside the loss of the second allele and therefore the biochemical features of truncated APC resulting from the germline mutation are sufficient to allow tumorigenesis. However, 16 exceptions do not respect the 20R1 rule, because in these cases all Figure 4 (a) The 15R-A provides the highest affinity b-catenin-binding site in truncated APC. Immunoprecipitation experiments using the indicated constructs and performed as described in the legend of Figure 3c. (b) , The 15R-C is involved in b-catenin degradation, whereas the 15R-D is not sufficient. Transcriptional and immunofluorescence assays using the constructs indicated in a, and performed as described in the Figure 1 legend. *Po0.02, using the Student's t-test.
truncating mutations fall before the 20R1 (before position 1271) ( Figure 5 ). When we analysed the distribution of the somatic APC mutations in these tumours as a function of the position of the germline hit ( Figure 5 ), we found that 14 out of 16 tumours express at least one truncated APC molecule containing at least the 15R-A. In addition, when the germline mutation falls after position 1053 and therefore allows the retention of the 15R-A, we observed that the second allele is lost in the majority of cases (8 cases out of 11 tumours), indicating that the presence of the 15R-A is sufficient for tumorigenesis. We concluded that truncated APC are selected for the presence of the 15R-A within the group of exceptional tumours.
Discussion
Individual contributions of the 15R to b-catenin degradation By combining site-directed mutagenesis and deletion analysis of APC with transient transfection assays, we have demonstrated that b-catenin binding to the 15R is necessary and sufficient to efficiently target b-catenin for degradation in a truncated APC molecule lacking the 20R3 and the SAMP repeats but containing the CID domain. A detailed analysis of the individual participations of the 15R to APC-mediated degradation of b-catenin revealed that they can work independently of each other but their relative contributions to the overall activity of the 15R region are not equivalent. The 15R-A turned out to display the highest affinity toward b-catenin among all binding sites of the 15R-20R1 module (Figure 4 and supplementary Figure 3) . It was also sufficient to provide a relatively good b-catenin downregulating activity to truncated APC (Figure 3) . The importance of the 15R-A is illustrated by the recent discovery of a rare substitution at amino acid position 1026 in the 15R-A, that has been shown to alter b-catenin binding to the repeat and to co-segregate systematically with attenuated FAP (Menendez et al., 2008) . The 15R-B could also mediate b-catenin degradation on its own (Figure 3a) but to a lesser extent than the 15R-A, likely due to a lower affinity for b-catenin (Figure 3b ). Finally, we could also reveal a contribution of the 15R-C, but not of the 15R-D (Figure 4) . It is still possible that the 15R-D plays a role in b-catenin degradation and that a low affinity for b-catenin may prevent detecting binding and downregulating activities. Alternatively, these functions of the 15R-D may depend on the other 15R.
Together, our results are compatible with two models of b-catenin degradation mediated by the 15R of APC. The high affinity of the 15R-A for b-catenin may allow APC to process low concentrations of b-catenin whereas the other 15R with a lower affinity to engage simultaneously several b-catenin molecules when its concentration increases. Alternatively, b-catenin binding to the 15R-A first may stimulate cooperative binding to the other remaining 15R, as suggested by the evidence of a cooperative activity between the 15R-A and 15R-B (Figure 3b ).
The 20R1 is neither necessary nor sufficient for b-catenin degradation The lack of effect observed in the immunofluorescence and transcriptional assays after mutating the 20R1 (Figure 2 ) may have resulted from the conditions of ectopic expression where the 20R1 would be dispensable. However, truncated APC containing mutant 15R but wild-type 20R1 could not target b-catenin for degradation (Figure 2 ), although the 20R1 could be phosphorylated and thus could bind relatively efficiently to b-catenin (Figure 4) . In comparison, mutation of the 15R-B clearly revealed its involvement in b-catenin downregulation, although we could not detect any b-catenin binding to it (Figure 4) . Thus, the 20R1 is either not involved in b-catenin degradation, or its function depends on b-catenin binding to the 15R region first. (Lamlum et al., 1999; Rowan et al., 2000; Albuquerque et al., 2002; Crabtree et al., 2003) (227 tumours out of 328). This was made for the sake of simplicity, because the CID is also a parameter of the interdependent bi-allelic selection of APC mutations. Truncations occurring between residues 1270-1284 (two tumours) were excluded, as the consequence on b-catenin binding to the 20R1 was not clear. Among all tumours shown here, there was no mutation falling between positions 1020 and 1053. The dark bars indicate tumours with truncating mutations always occurring before the 20R1. LOH, loss of heterozygocity. Po10 À8 using the Fischer's exact test for the comparison of tumour distribution in every germline category.
In contrast to the 20R1, the 20R2 cannot bind to b-catenin (Liu et al., 2006; Kohler et al., 2008) whereas the 20R3 is sufficient for b-catenin binding (Kohler et al., 2008) and degradation (supplementary Figure 1) . The APC sequence contains four supplementary 20Rs that still await a functional analysis, as it is not possible to predict their involvement in b-catenin degradation in view of their sequence homology and even their affinity for b-catenin, by analogy with the 20R1 that displays a relatively high affinity for b-catenin, though is not sufficient to target it for degradation.
One model of APC-mediated degradation of b-catenin relies on the mutually exclusive abilities of axin and the 20R3 to bind to b-catenin and to compete for it (Xing et al., 2003; Ha et al., 2004) . According to this model, axin-bound b-catenin is phosphorylated by CK1 and GSK3b. Subsequent phosphorylation of the 20R3 increases its affinity for b-catenin, allowing the displacement of phosphorylated b-catenin from axin and its transfer onto APC. Our results indicate that the phosphorylated 20R1 does not mediate b-catenin degradation and others have shown that it displays a lower affinity for b-catenin than the phosphorylated 20R3 (Liu et al., 2006) that can perform the function. This suggests that the phosphorylated 20R1 cannot target b-catenin for degradation because it may not be able to compete with axin for b-catenin binding. However, our results reveal also that the 15R-B can promote b-catenin degradation although it displays a lower affinity for b-catenin than the 20R1. Therefore, the differences of affinities of the 20R1 and the 20R3 for b-catenin do not explain their functional differences in the context of the model. Alternatively, the 15Rs and the 20Rs may have different roles in b-catenin degradation.
The SAMP repeat compensates for the lack of b-catenin binding When a SAMP repeat is present in truncated APC, b-catenin binding to APC is not necessary anymore to target b-catenin for degradation (Figure 1 ). This result contradicts apparently the conclusions of other authors (Kawahara et al., 2000) who showed that an internal APC fragment spanning amino acids 1342-1887, and therefore retaining the SAMP repeats, requires the 20Rs to target b-catenin for degradation in SW480 cells. The presence of the N terminus of APC in our constructs, which seems to contribute to b-catenin downregulation (Kohler et al., 2009) , may provide a compensation to the lack of b-catenin binding.
Our observation that the presence of a SAMP repeat probably alleviates the requirement of b-catenin-binding stems from the combination of two facts. First, although we also performed some of our transcriptional assays under limiting conditions (data not shown), the concentration of exogenous APC construct was probably higher than the level reached by endogenous full length APC in natural conditions. Second, our constructs were transfected in the SW480 colorectal cancer cell line known to express relatively high levels of axin2/ conductin. As it has also been established that ectopic expression of axin2/conductin alone leads already to efficient b-catenin degradation in SW480 cells expressing an inactive endogenous truncated APC lacking all SAMP repeats and the CID domain (Behrens et al., 1998) , we think that both upregulation of endogenous axin2/conductin and ectopic expression of a truncated APC construct containing a SAMP repeat, but lacking functional b-catenin sites is sufficient for the b-catenin degradation machinery to bypass b-catenin binding to APC, which is thought nevertheless to occur under physiological conditions. Actually, the multiplicity of SAMP repeats and b-catenin-binding sites in APC and the fact that either domain is not strictly necessary to achieve a high b-catenin degrading activity confirm the recently described robustness of the degradation complex (Peterson-Nedry et al., 2008) .
The 15R-A is a parameter of the selection of truncated APC in colorectal cancer In colorectal tumours, truncating mutations affecting APC occur after the 20R1 in the vast majority of cases (Lamlum et al., 1999; Albuquerque et al., 2002; Crabtree et al., 2003; Miyaki et al., 2008) . In tumours that do not respect this rule, the 15R-A seems to be the target of the selection of APC-truncating mutations ( Figure 5 ). The selective pressure on APC mutations is different in colorectal, duodenal, desmoid and breast tumours. Colorectal APC mutations have the tendency to fall before the CID domain (Kohler et al., 2009) , whereas truncated APCs from duodenal (Groves et al., 2002) and desmoid (Latchford et al., 2007) tumours rather keep the CID domain while simultaneously avoiding the presence of the 20R3 (Kohler et al., 2009) . In contrast, the presence of the 20R3 is clearly selected in truncated APC from breast tumours (Kuraguchi et al., 2009 ). Although there is increasing evidence that colorectal tumours derive from crypt stem cells (Barker et al., 2009) , we suggest that the 16 tumours in which the selection has been acting on the 15R-A may have arose from a specific cell type.
Altogether, this work has revealed the involvement of the 15R in b-catenin degradation mediated by truncated APC. The 15R-A provides the highest affinity b-catenin-binding site in the 15R-20R1 module and is one target of the selection of APC-truncating mutations in colorectal cancer. It would be interesting now to determine the consequences of mutating the 15Rs and/or the 20Rs on tumour location and development in truncated APC from the currently available mouse models, namely the APC 1638T (Smits et al., 1999) , APC þ /1572T (Gaspar et al., 2009) and APC þ /1322T (Pollard et al., 2009) mice. As the affinity of the 15R-A for b-catenin is higher than that of the 20R1, it is puzzling that most colorectal tumours are selected for the presence of the 20R1 in truncated APC.
Materials and methods

Cells
Cells are described in Supplementary information.
